RELMADA THERAPEUTICS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Relmada Therapeutics, Inc. on May 23, 2025. The company is incorporated in Nevada and its common stock trades on The Nasdaq Global Select Market under the symbol RLMD.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Of the 33,191,622 shares eligible to vote, 17,793,346 shares (approximately 53.6%) were present and voted. The following matters were approved:
- Election of Directors: John Glasspool was elected as a Class I Director for a 36-month term. He received 7,144,974 votes "For," 2,600,170 "Withheld," and 8,048,202 Broker Non-Votes. Continuing directors include Charles J. Casamento, Sergio Traversa, and Paul Kelly.
- Ratification of Auditors: Stockholders approved the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 16,438,370 "For," 862,968 "Against," and 492,008 "Withheld."
- Equity Plan Amendment: Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares available for issuance by 2,000,000, bringing the aggregate total to 9,900,000 shares. The vote was 6,687,532 "For," 2,585,688 "Against," and 471,924 "Withheld."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a disclosure of the Annual Meeting results.
Key Facts for Investor Verification
- Verify the impact of the 2,000,000 share increase in the 2021 Equity Incentive Plan on potential future dilution.
- Confirm the tenure and responsibilities of the newly elected Class I Director, John Glasspool.
- Review the 2025 Proxy Statement (filed April 11, 2025) for detailed descriptions of the equity plan amendment.
- Note that CBIZ CPAs P.C. has been ratified as the auditor for the fiscal year ending December 31, 2025.